Selection

EVERI REPORTS FIRST QUARTER 2023 RESULTS

Retrieved on: 
Wednesday, May 10, 2023
Insurance, Share repurchase, Contact, Selection, Tax, PDT, Fintech, GAAP, Research, Generally Accepted Accounting Principles (United States), EDT, Forecasting, Tablet, Public expenditure, PIN, EBITDA, Acquisition, Everi Holdings, Regulatory technology, Loyalty, Growth, Depreciation, EPS, Adjustment, Hand, Software, Bookkeeping, Video game, Cryptocurrency, Bank, Cash

LAS VEGAS, May 10, 2023 /PRNewswire/ -- Everi Holdings Inc. (NYSE: EVRI) ("Everi" or the "Company"), today announced results for the first quarter ended March 31, 2023.

Key Points: 
  • Software and other revenues, which include Loyalty and RegTech software, product subscriptions, kiosk maintenance services, and other revenues, rose 35% to $24.2 million in the first quarter of 2023 compared to $17.9 million in the first quarter of 2022.
  • Approximately 72% and 80% of software and other revenues were of a recurring nature in the 2023 and 2022 first quarter periods, respectively.
  • Total debt decreased to $986.5 million at March 31, 2023, from $992.5 million as of December 31, 2022, as the Company paid $6.0 million on its secured term loan during the 2023 first quarter.
  • The Company will host an investor conference call to discuss its 2023 first quarter results at 11:00 a.m. EDT (8:00 a.m. PDT) today.

Casa Systems Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
Cloud, Interim, Communication, Failure, Table, Tier 1, Selection, COVID-19, GAAP, Risk, Economics, Sale, Mobile secure gateway, Public expenditure, MNO, EBITDA, Traction, Distributed Access Control System, Acquisition, Annual report, Access, Radio, Webcast, Depreciation, Verizon Communications, LG, Security (finance), Environment, TLB, Conference, TSA, Manufacturing Consent, Software, Bank, Cryptocurrency, Bookkeeping, Commercial property

ANDOVER, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Casa Systems, Inc. (Nasdaq: CASA), a leading provider of cloud-native software and physical broadband technology solutions for access, cable, and cloud, today reported its financial results for the first quarter ended March 31, 2023.

Key Points: 
  • ANDOVER, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Casa Systems, Inc. (Nasdaq: CASA), a leading provider of cloud-native software and physical broadband technology solutions for access, cable, and cloud, today reported its financial results for the first quarter ended March 31, 2023.
  • For the fiscal year 2023, the Company currently expects:
    Casa Systems is hosting a conference call for analysts and investors to discuss its financial results for the first quarter ended March 31, 2023, and its business outlook at 6:00 p.m. Eastern Time today, May 9, 2023.
  • All statements other than statements of historical fact contained in this press release, including statements regarding the projected results of operations and financial position of Casa Systems, Inc. (“Casa Systems” or "Casa" or the “Company” or “we”), including financial targets, business strategy, our plans to refinance the 2023 TLB Debt, and plans and objectives for future operations, are forward-looking statements.
  • For the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures, please see the section of the accompanying tables titled, “Reconciliation of Selected GAAP and Non-GAAP Financial Measures.”

Freshworks Reports First Quarter 2023 Results

Retrieved on: 
Tuesday, May 2, 2023
Exercise, Uncertainty, Table, Customer, Marketing, Selection, Tax, GAAP, USD, Checked tone, EUR, Investment, ARR, Bank, Reinsurance, Insurance

(3) Non-GAAP net income per share was estimated assuming 291.9 million and 298.2 million weighted-average shares outstanding for the second quarter and full year 2023, respectively.

Key Points: 
  • (3) Non-GAAP net income per share was estimated assuming 291.9 million and 298.2 million weighted-average shares outstanding for the second quarter and full year 2023, respectively.
  • Refer to the “Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.
  • We have provided a reconciliation of other GAAP to non-GAAP financial measures in the financial statement tables for our first quarter and full year 2023 non-GAAP results included in this press release.
  • We will host a conference call for investors on May 2, 2023 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the company’s financial results and business highlights.

Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data

Retrieved on: 
Monday, May 1, 2023
CRISPR, Drug development, Selection, IPSC, Gene editing, NK, Cell, Editas Medicine, Transgene, Engineering, Nature Biotechnology, Neoplasm, Genome, Fine chemical, Vaccine

CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) gene editing technology.

Key Points: 
  • CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) gene editing technology.
  • Despite major progress in achieving gene disruption with CRISPR-Cas gene editing technologies, efficient knock-in of transgenes continues to be a significant challenge for the gene editing field.
  • “We are thrilled Nature Biotechnology published our paper sharing the comprehensive data on our SLEEK gene editing technology as we believe SLEEK has immense potential for gene editing drug development.
  • The SLEEK technology remains an important Editas capability in iPSC engineering for a wide variety of future applications.

Barbra Streisand Awarded Tenth Anniversary Genesis Prize

Retrieved on: 
Monday, May 1, 2023
Bloomberg Philanthropies, Genesis Prize, Partnership, Ambassador, GPF, Selection, COVID-19, World Trade Center, First lady, Woman, Genesis, Human, Multimedia, Organization, NGO, Bloomberg, Ceremony, Lower Manhattan, Time (magazine), Performing Arts Center, Health, TIME, Environment, Family, Bloomberg L.P., Pharmaceutical industry, Hospital, United, Jews, Pfizer

NEW YORK, May 1, 2023 /PRNewswire/ -- Today, The Genesis Prize Foundation (GPF) announced iconic actor, singer, director, author, and activist Barbra Streisand as the 10th Anniversary Genesis Prize Laureate.

Key Points: 
  • NEW YORK, May 1, 2023 /PRNewswire/ -- Today, The Genesis Prize Foundation (GPF) announced iconic actor, singer, director, author, and activist Barbra Streisand as the 10th Anniversary Genesis Prize Laureate.
  • Since the launch of the Prize in 2013, Ms. Streisand has received tens of thousands of nominations and votes for the Genesis Prize.
  • Recognizing the overwhelming display of support and admiration by global Jewry over the past decade, the judges of the Selection and Prize Committees unanimously endorsed Ms. Streisand as the 10th Anniversary Genesis Prize Laureate.
  • Barbra Streisand said: "I am delighted to be honored by the special 10th Anniversary Genesis Prize and to work with The Genesis Prize Foundation to support organizations that seek to better society and our shared humanity.

Barbra Streisand Awarded Tenth Anniversary Genesis Prize

Retrieved on: 
Monday, May 1, 2023
Bloomberg Philanthropies, Genesis Prize, Partnership, Ambassador, GPF, Selection, COVID-19, World Trade Center, First lady, Woman, Genesis, Human, Organization, NGO, Bloomberg, Ceremony, Lower Manhattan, Time (magazine), Performing Arts Center, Health, TIME, Environment, Family, Bloomberg L.P., Pharmaceutical industry, Hospital, United, Jews, Pfizer

NEW YORK, May 1, 2023 /PRNewswire/ -- Today, The Genesis Prize Foundation (GPF) announced iconic actor, singer, director, author, and activist Barbra Streisand as the 10th Anniversary Genesis Prize Laureate.

Key Points: 
  • NEW YORK, May 1, 2023 /PRNewswire/ -- Today, The Genesis Prize Foundation (GPF) announced iconic actor, singer, director, author, and activist Barbra Streisand as the 10th Anniversary Genesis Prize Laureate.
  • Since the launch of the Prize in 2013, Ms. Streisand has received tens of thousands of nominations and votes for the Genesis Prize.
  • Recognizing the overwhelming display of support and admiration by global Jewry over the past decade, the judges of the Selection and Prize Committees unanimously endorsed Ms. Streisand as the 10th Anniversary Genesis Prize Laureate.
  • Barbra Streisand said: "I am delighted to be honored by the special 10th Anniversary Genesis Prize and to work with The Genesis Prize Foundation to support organizations that seek to better society and our shared humanity.

Delta's Ed Bastian Named Chief Executive Magazine's 2023 CEO of The Year

Retrieved on: 
Monday, May 1, 2023
The Wall Street Journal, Ed Bastian, Selection, Delta Air Lines, Attention, History, FlightGlobal, Bausch & Lomb, Organization, Warburg Pincus, AlixPartners, Bank of America, COVID-19, Health, Bankruptcy, Aircraft, Management, Airline, Delta, Merck

BRENTWOOD, Tenn., May 1, 2023 /PRNewswire/ -- Chief Executive magazine today announced that Ed Bastian, CEO of Delta Air Lines, has been named 2023 Chief Executive of the Year by his peer CEOs.

Key Points: 
  • BRENTWOOD, Tenn., May 1, 2023 /PRNewswire/ -- Chief Executive magazine today announced that Ed Bastian, CEO of Delta Air Lines, has been named 2023 Chief Executive of the Year by his peer CEOs.
  • "Ed Bastian is a true exemplar of what it means to be a visionary, resilient, purpose-driven leader," said Ken Frazier, former chair and CEO of Merck and our 2021 CEO of the year, who served on this year's selection committee.
  • A 25-year Delta veteran, Bastian is credited with transforming the company through generational investments in technology, aircraft and airport facilities.
  • Bastian's selection as 2023 CEO of the Year is scheduled to be celebrated at an invitation-only event hosted by Chief Executive Group this fall.

Indianapolis Prize Officials Name Peruvian Primatologist and Anthropologist Winner of Inaugural Emerging Conservationist Award

Retrieved on: 
Tuesday, April 18, 2023
Google Drive, Interview, Indianapolis Prize, Education, Selection, Mammal, Science and Technology Select Committee, Stony Brook University, Research, Forest, Indianapolis Zoo, Ministry, Central Commission for Discipline Inspection, Ministry of Women and Vulnerable Populations, All but dissertation, Nature, Primate, Medal, Economic development, Dropbox, Cummins, Conservationist, Forestry, Hunting, Winner, Woman

INDIANAPOLIS, April 18, 2023 /PRNewswire/ -- Officials from the Indianapolis Prize, the world's leading award for animal conservation, today named Peruvian primatologist and anthropologist Fanny M. Cornejo the 2023 Winner of the Inaugural Emerging Conservationist Award. The biennial Award recognizes and supports conservationists under 40 years of age with the talent and drive to make a significant impact on saving an animal species or group of species.

Key Points: 
  • INDIANAPOLIS, April 18, 2023 /PRNewswire/ -- Officials from the Indianapolis Prize, the world's leading award for animal conservation, today named Peruvian primatologist and anthropologist Fanny M. Cornejo the 2023 Winner of the Inaugural Emerging Conservationist Award.
  • Undoubtedly, being the first winner of the Emerging Conservationist Award and from an organization as important as the Indianapolis Prize is a great recognition for our work in Peru," said Fanny Cornejo, Winner of the Indianapolis Prize's inaugural Emerging Conservationist Award.
  • Cornejo will be formally recognized as the 2023 Emerging Conservationist at the Indianapolis Prize Gala presented by Cummins Inc. in downtown Indianapolis on Sept. 30, 2023.
  • A press kit with videos, photos and an interview with the 2023 Emerging Conservationist Award Winner can be accessed via Dropbox or Google Drive .

Freddie Mac Lists Securities Transitioning from LIBOR, Together with Fallback Reference Rates

Retrieved on: 
Thursday, April 13, 2023
Benchmark, Transfer, Housing, FMCC, Consumer, ICE, LIBOR, Selection, SOFR, OTCQB, USD, Residential mortgage-backed security, SPCS, Investment, Freddie Mac, CUSIP, Giant

MCLEAN, Va., April 13, 2023 (GLOBE NEWSWIRE) -- Freddie Mac (OTCQB: FMCC) today posted to its website a list of more than 34,000 Freddie Mac floating-rate securities transitioning from LIBOR to replacement indices based on the Secured Overnight Financing Rate (SOFR).

Key Points: 
  • MCLEAN, Va., April 13, 2023 (GLOBE NEWSWIRE) -- Freddie Mac (OTCQB: FMCC) today posted to its website a list of more than 34,000 Freddie Mac floating-rate securities transitioning from LIBOR to replacement indices based on the Secured Overnight Financing Rate (SOFR).
  • “Freddie Mac today moved another step closer to completing its years-long transition from LIBOR to new SOFR-based reference rates,” said Karen Pilewski, senior director and lead for Freddie Mac LIBOR transition implementation.
  • “The assignment of a fallback reference rate to every remaining LIBOR-indexed Freddie Mac security offers market participants added confidence that their investments will transition seamlessly to the replacement index at LIBOR’s cessation.”
    The securities include Freddie Mac Participation Certificates, Giants, Collateralized Mortgage Obligations, Credit Risk Transfer securities and Multifamily PCs and SPCs for which Freddie Mac is responsible for selecting the replacement index.
  • To view the list and learn more about the LIBOR transition, please visit the Freddie Mac Reference Rates Transition webpage .

Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, April 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Selection, Abstract, TILS, AACR, University, American Association for Cancer Research, Annual general meeting, Pharmaceutical industry

Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat solid tumors, today announced that two abstracts have been accepted for poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando, Florida, April 14-19, 2023.

Key Points: 
  • Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat solid tumors, today announced that two abstracts have been accepted for poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando, Florida, April 14-19, 2023.
  • The presentations include preclinical data for TIDAL-01, Turnstone’s lead tumor-infiltrating lymphocyte therapy candidate based on the selection of tumor-reactive T cells (Selected TILs), which is currently being evaluated in two Phase 1b trials, as well as data showcasing an additional strategy for tumor-reactive T cell selection.
  • “We look forward to sharing preclinical data at the AACR Annual Meeting which continue to validate the exciting potential of our next-generation Selected TILs across a wide range of solid tumors,” said Stewart Abbot, Ph.D., Chief Scientific Officer, Turnstone Biologics.
  • Full abstracts are available through the AACR conference website, and details of the poster presentations are as follows: